Key clinical point:
Major finding: Antenatal betamethasone treatment was linked to $4,681 per mother-infant pair, compared with $5,379 without corticosteroids (P = .02 for $698 difference).
Study details: The findings are based on a secondary analysis of a randomized clinical trial from October 2010 to February 2015 involving 2,821 mothers at high risk for preterm birth, and their infants.
Disclosures: The National Institutes of Health funded the research. Dr. Gyamfi-Bannerman received a grant from AMAG pharmaceuticals during the conduct of the study.
Gyamfi-Bannerman C. JAMA Pediatr. 2019 Mar 11.
This Week's Must Reads
Outpatient Utilization Patterns for AD in the US, J Am Acad Dermatol; ePub 2019 Mar 15; Singh, et al
Racial Disparities in Healthcare Utilization for AD, J Invest Dermatol; ePub 2019 Mar 13; Wan, et al
Sleep Disturbances in Mothers of Children with AD, JAMA Dermatol; ePub 2019 Mar 20; Ramirez, et al
Childhood AD in the Primary Care Setting, J Am Board Fam Med; 2019 Mar-Apr; Al-Naqeeb, et al